Evidence map›Paper›PMID 37662328›Full record

ArticlebioRxiv : the preprint server for biology2023

PLATELET FACTOR 4 (PF4) IMPROVES SURVIVAL IN A MURINE MODEL OF ANTIBIOTIC-SUSCEPTIBLE AND METHICILLIN-RESISTANT

Nataly P Podolnikova, Valeryi K Lishko, Robert Roberson, Zhqian Koh, Dmitry Derkach, David Richardson, Michael Sheller, Tatiana P Ugarova

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nataly P PodolnikovaSchool of Life Sciences, Arizona State University, Tempe, AZ 85287.
Valeryi K LishkoSchool of Life Sciences, Arizona State University, Tempe, AZ 85287.
Robert RobersonSchool of Life Sciences, Arizona State University, Tempe, AZ 85287.
Zhqian KohSchool of Life Sciences, Arizona State University, Tempe, AZ 85287.
Dmitry DerkachbioSyntagma Inc., Tempe, AZ 85287.
David RichardsonbioSyntagma Inc., Tempe, AZ 85287.
Michael ShellerSchool of Life Sciences, Arizona State University, Tempe, AZ 85287.
Tatiana P UgarovaSchool of Life Sciences, Arizona State University, Tempe, AZ 85287.
Arizona State University · US

Funding

The role of beta 2 integrins in macrophage fusionR01HL063199 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Tatiana P Ugarova · 1999 to 2026
$8.6M
Leica TCS SP8 Laser Scanning Confocal MicroscopeS10OD023691 · OD · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI BALUCH, DEBRA PAGE · 2017 to 2017
$600k
NHLBI NIH HHS R01 HL063199NIH HHS S10 OD023691
6 · The paper itself

Abstract

The complement receptor CR3, also known as integrin Mac-1 (CD11b/CD18), is one of the major phagocytic receptors on the surface of neutrophils and macrophages. We previously demonstrated that in its protein ligands, Mac-1 binds sequences enriched in basic and hydrophobic residues and strongly disfavors negatively charged sequences. The avoidance by Mac-1 of negatively charged surfaces suggests that the bacterial wall and bacterial capsule possessing net negative electrostatic charge may repel Mac-1 and that the cationic Mac-1 ligands can overcome this evasion by acting as opsonins. Indeed, we previously showed that opsonization of Gram-negative

Indexed as

antibiotic resistanceantimicrobial activityCD11b/CD18CR3CXCL4integrin Mac-1PF4phagocytosis

Identifiers

PMID37662328
PMCPMC10473751
OpenAlexW4386203367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.